[Company Profile] MicroPhage
MicroPhage of Longmont, Colo., has developed a platform of rapid diagnostic tests to identify staph bacteria and determine methicillin resistance (MRSA) and susceptibility (MSSA).
News
ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy
ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.
[Company Profile] Stentys
Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.
Bioguard Wound Dressings Beat Swine Flu In Independent Study
Derma Sciences, a developer of wound care products, announced that its Bioguard Barrier Dressings effectively safeguarded against the H1N1 “swine flu” virus in an independent laboratory study.
Celgene Acquires Gloucester In $340M Deal
Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.
Vertex to Sell 1.5 Million Shares
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
Hope for Epilepsy Patients, But Treatment Gap Exists Worldwide
An exciting discovery may change the way epilepsy is treated, but if current evidence is any indication, getting the treatment to patients will be a challenge.
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
FDA Approves Treatment for Rare Swelling Disease
Biopharmaceutical company Dyax Corporation has received regulatory approval to market its drug ecallantide (Kalbitor) for a rare genetic disorder called hereditary angioedema (HAE).